Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesSaniona AB

Saniona AB

PortfolioPortfolio WatchlistWatchlist
Company price
11.0 GBX -0.01 ( 0.09%)
Last update at 2026-10-27T11:57:00Z
VOLUME
172
Market Cap
280.82M

Momentum Score

…

Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company's product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical trial to treat people with obesity; and Tesomet, an oral investigational therapy, which is in Phase 2b clinical trial for the treatment of hypothalamic obesity and Prader-Willi syndrome; and ACP-711, a positive allosteric modulator of GABAA a3 containing receptors that has completed Phase 1 clinical trial for the treatment of essential tremor, a neurological disorder. It also develops SAN903, a novel medicine based on inhibition of the calcium-activated potassium ion channel, which has completed preclinical development for the treatment of inflammatory bowel disease; SAN2219, a subtype selective positive allosteric modulator of GABAA a2- a3- and a5 that is in preclinical stage for treatment of acute repetitive seizures; SAN2355 to treat resistant focal onset seizures; and SAN2465, a negative allosteric modulator to treat major depressive disorder. In addition, the company's other programs to treat epilepsy, Alzheimer's, schizophrenia, and migraine. It has research and collaboration agreements with Boehringer Ingelheim International GmbH to research, develop, manufacture, and commercialize therapeutics; license agreement with Productos Medix, S.A. de C.V. develop and commercialize tesofensine and/or Tesomet; research services agreement and a collaboration agreement with Cephagenix ApS to identify and develop novel migraine treatments; and research collaboration with AstronauTx to research, develop, manufacture, and commercialize therapeutics for Alzheimer's disease. Saniona AB (publ) was founded in 2011 and is headquartered in Glostrup, Denmark.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
11.00
Low
11.00
High
52 Week Price Range
6.13
Low
28.15
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Saniona AB is a clinical-stage biopharmaceutical company developing therapies that target ion channels and transporters for neurological, metabolic and rare diseases. Long-term growth may be driven by clinical trial progress, successful licensing or partnering of programs and advancement of its discovery pipeline. It appears positioned to capture value from positive clinical readouts and partnering opportunities if programs advance.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
11.01
Dividend Yield
-
Revenue TTM
434.40M
Revenue Per Share
3.37
Gross Profit TTM
428.97M
Debt / Equity
0.03
ROE
65.67%
Net Debt
-
ROCE
-30.72%
Diluted EPS TTM
-7.39

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax - - -81.22M -76.46M -48.29M
Net income - - -73.43M -68.75M -41.06M
Selling general administrative - - 62.42M 25.94M 24.22M
Gross profit - - -92.16M -65.49M -29.35M
Ebit -191.02M -411.57M -157.98M -93.63M -54.20M
Operating income - - -106.05M -93.63M -54.21M
Interest expense - 0.00M 0.00M 0.00M 0.00M
Tax provision - - -7.79M -7.71M -7.23M
Interest income - - 24.83M 17.16M 5.91M
Income tax expense -6.61M -7.48M -7.79M -7.71M -7.23M
Total revenue - - 8.20M 7.20M 54.88M
Cost of revenue - - 100.36M 72.69M 84.24M
Net income applicable to common shares -245.36M -410.90M -73.43M -68.75M -41.06M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets - - 692.18M 94.81M 83.08M
Intangible assets - - 6.07M 7.68M -
Other current assets 2.78M 0.85M 0.22M 1.20M -
Total liab - - 88.72M 40.92M 43.62M
Total stockholder equity - - 603.46M 53.88M 39.46M
Other current liab 3.00M 0.69M 5.62M 1.07M 26.56M
Common stock 3.12M 3.12M 3.12M 1.42M 1.17M
Retained earnings -872.26M -608.93M -245.18M -183.83M -118.05M
Other liab 2.39M 92.97M 2.08M 0.73M 0.00M
Other assets 3.11M 20.79M 2.61M 0.37M 4.06M
Cash - - 573.87M 40.25M 54.68M
Total current liabilities 22.90M 65.28M 70.42M 38.78M 43.62M
Short term debt - - 24.35M - 6.00M
Short long term debt total - - 16.23M 1.42M -
Other stockholder equity 108.59M 74.55M 36.91M -3.30M -0.78M
Property plant equipment 15.70M 21.75M 28.12M 3.41M 1.84M
Total current assets 127.34M 390.84M 595.81M 52.89M 70.67M
Net tangible assets 45.97M 275.81M 597.39M 46.20M 39.46M
Net receivables 12.86M 13.24M 16.20M 9.92M 14.31M
Accounts payable 14.07M 29.11M 18.88M 34.85M 7.24M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments - 7.52M 44.65M 104.51M 104.51M
Change to liabilities - 0.00M 0.00M 0.00M 0.00M
Total cashflows from investing activities - 6.84M 43.16M 99.51M -0.75M
Net borrowings - -20.52M 50.36M 22.67M 24.00M
Total cash from financing activities - -20.52M 50.60M 621.18M 76.73M
Change to operating activities - -17.55M 28.68M 14.95M -10.88M
Net income -95.81M -245.36M -410.90M -73.43M -68.75M
Change in cash - -245.15M -217.01M 533.62M -14.43M
Total cash from operating activities - -281.54M -345.04M -174.28M -98.59M
Depreciation - 7.82M 8.67M 3.40M 2.20M
Other cashflows from investing activities - - - 104.51M 2.74M
Change to account receivables - - -3.76M -34.91M -7.89M
Sale purchase of stock - - - 598.51M 52.73M
Other cashflows from financing activities - - -0.08M -52.73M -52.73M
Change to netincome - -26.44M 32.26M -84.30M -13.26M
Capital expenditures 0.00M 0.98M 1.48M 5.00M 3.49M
Change in working capital - - - -13.09M -10.87M

Peer Comparison*

Sector: Industry:

Stock Name
Change
(GBX)
Price
(GBX)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
0RQJ
Saniona AB		 -0.01
0.09%		 11.00 - - 0.65 -
0R15
SoftBank Group Corp.		 248.00
5.84%		 4494.00 - - - -
0R1E
Nintendo Co. Ltd.		 -115.00
1.34%		 8476.00 - - - -
0LC3
Synchrony Financial		 2.34
3.20%		 75.60 0.09 - 4.97 -
0HQP
CBRE Group Inc. Cl A		 0.15
0.12%		 122.47 0.25 - 1.18 -

Profile*

Saniona AB

Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company's product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical trial to treat people with obesity; and Tesomet, an oral investigational therapy, which is in Phase 2b clinical trial for the treatment of hypothalamic obesity and Prader-Willi syndrome; and ACP-711, a positive allosteric modulator of GABAA a3 containing receptors that has completed Phase 1 clinical trial for the treatment of essential tremor, a neurological disorder. It also develops SAN903, a novel medicine based on inhibition of the calcium-activated potassium ion channel, which has completed preclinical development for the treatment of inflammatory bowel disease; SAN2219, a subtype selective positive allosteric modulator of GABAA a2- a3- and a5 that is in preclinical stage for treatment of acute repetitive seizures; SAN2355 to treat resistant focal onset seizures; and SAN2465, a negative allosteric modulator to treat major depressive disorder. In addition, the company's other programs to treat epilepsy, Alzheimer's, schizophrenia, and migraine. It has research and collaboration agreements with Boehringer Ingelheim International GmbH to research, develop, manufacture, and commercialize therapeutics; license agreement with Productos Medix, S.A. de C.V. develop and commercialize tesofensine and/or Tesomet; research services agreement and a collaboration agreement with Cephagenix ApS to identify and develop novel migraine treatments; and research collaboration with AstronauTx to research, develop, manufacture, and commercialize therapeutics for Alzheimer's disease. Saniona AB (publ) was founded in 2011 and is headquartered in Glostrup, Denmark.

Murervangen 42, Glostrup, Denmark, 2600

45 70 70 52 25

https://www.saniona.com

34

Name Title Year Born
Mr. Jorgen Drejer Ph.D. Founder, Chairman & Deputy CEO 1955
Mr. Rami Levin Pres 1969
Mr. Thomas Feldthus M.Sc., MBA Co-Founder & CEO 1960
Ms. Anita Milland B.Com. Chief Financial Officer 1968
Mr. Karin Sandager Nielsen Ph.D. Chief Scientific Officer NA
Mr. Palle Christophersen M.S., Ph.D. Exec. VP of Research 1958
Mr. Janus Schreiber Larsen Chief Devel. Officer 1972
Mr. Jorgen Drejer Ph.D. Founder, Deputy CEO & Deputy Chairman of the Board 1955
Dr. Pierandrea Muglia M.D. Chief Medical Officer 1966
Mr. Johnny Stilou M.S. Chief Financial Officer 1967

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…